First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
Editorial
We have improved our eMediNexus Platform with a far superior user experience.
Please click here to try it
Editor-in-Chief eMediNexus – Dr KK Aggarwal
 
30th August 2018
Antihypertensive treatment plus a statin has long-term mortality benefits

Dr KK Aggarwal, Recipient of Padma Shri

Blood pressure and cholesterol lowering drugs improve survival in patients with hypertension even after more than a decade, suggest results from the ASCOT Legacy study presented at ESC Congress 20181 and published simultaneously in The Lancet.

The ASCOT Legacy study is the long-term follow-up of more than 8000 hypertensive patients from the UK, almost 16 years after they had had been recruited in the multicenter Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), between 1998 and 2000. The study participants also had three or more additional risk factors for cardiovascular disease.

In the BP lowering arm, patients who were treated with calcium channel blocker based treatment regimen (amlodipine) + perindopril, if needed for 5.5 years reduced their chances of stroke-related death over ten years by 29% in comparison to those taking an older regimen, based on atenolol (a beta-blocker) + bendroflumethiazide (a diuretic) and potassium, if needed. There was a non-significant trend towards 10% fewer cardiovascular deaths with the newer therapy. ....read more

Top News

Africa commits to ending cholera outbreaks by 2030

African Health Ministers have pledged to implement key strategies for ending cholera outbreaks in the African region by 2030. Forty-seven African countries adopted the Regional Framework for the Implementation of the Global Strategy for Cholera Prevention and Control today (28 August) at the 68th session of the World Health Organization’s Regional Committee for Africa, which is taking place in Dakar, Senegal... read more

Morning Medtalks

Morning MEDTalks with Dr KK Aggarwal 30th August 2018

Switching to oral antibiotics once an endocarditis patient is stable is safe and noninferior to continued intravenous antibiotic treatment as shown in the randomized Partial Oral Treatment of Endocarditis (POET) trial. The group getting oral tablets after at least 10 days of IV antibiotics had a 9.0% rate of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen by 6 months after completion of treatment. That rate was noninferior to the 12.1% in the IV-only antibiotic group .... read more

Practice Updates

Anxiety and depression increase risk of heart attack and stroke

Anxiety, depression and other mental distress was associated with an increased risk of heart attack and stroke among adults ages 45 or older, according to new research reported in Circulation: Cardiovascular Quality and Outcomes. High/very high psychological distress was... read more


US FDA approves the first tretinoin lotion for acne

The first lotion formulation of tretinoin has been approved by the US FDA. Once-daily tretinoin 0.05% lotion (Altreno, Ortho Dermatologics) can now be given for the treatment of acne vulgaris in patients aged 9 years and older... read more


Chemotherapy may lead to early menopause in young women with lung cancer

A new study published online in the journal Menopause suggests chemotherapy may cause acute amenorrhea leading to early menopause in women with lung cancer, who are younger than 50 years. Sixty-four percent of the 85 women who received chemotherapy, self-reported that they... read more


A prediction model to identify burn patients at risk of life-threatening respiratory disease

A prediction model using three factors has been devised to better predict burn patients who are most likely to develop life-threatening acute respiratory distress syndrome (ARDS) viz. the extent of the patient's inhalation injury, the percentage of the patient's body that was burned and... read more


A new antibiotic for complicated intra-abdominal infections

The US Food and Drug Administration (FDA) has approved injectable eravacycline (Xerava, Tetraphase Pharmaceuticals) for treatment of complicated intra-abdominal infections (cIAIs) in adults age 18 years and older. Eravacycline is a fully synthetic fluorocycline antibiotic, which... read more

eMedi Humor
Medicolegal Corner
eMedi Quiz
Mitsuda's reaction
Medina-Ramirez reaction
Fischer's test
Fernandez reaction
Lifestyle Updates
 
Inspirational Story 1: A most important lesson
Inspirational Story 2: A True friend
Manufacturing medicines and medical devices in India can pave way for Cure in India
There is a lack of access to essential medicines in India despite attempts to ensure wider availability
 
New Delhi, 29 August 2018: The Lok Nayak Hospital - one of the centrally located government hospitals in New Delhi - has run out of third-line treatment for HIV this week. Restoring supply will take about three to four days. The state needs about 10,000 doses of the third line combination drug Raltegravir + Darunavir + Ritonavir every month. These are centrally procured for the entire country by the National AIDS Control Organisation (NACO). The supply issues occurred due to problems in finalizing the tender.

Recent research has revealed the shocking lack of access to essential medicines in India, despite thousands being approved in an attempt to generate wider availability. It found that despite there being multiple approved products listed in India databases, few were available in private pharmacies at a price people could afford.

To Read More or Comment, Click Here